Pulmonary, Critical Care, and Sleep Division, Cincinnati Veterans Affairs Medical Center, Cincinnati, OH, USA.
Int J Chron Obstruct Pulmon Dis. 2010 Apr 7;5:89-97. doi: 10.2147/copd.s8822.
The relationship between prior health care utilization and respiratory medication prescriptions in an unselected population of patients with COPD is not known.
We determined the prescribed respiratory medications and respiratory and nonrespiratory health care encounters in 523 Veterans with COPD at the Cincinnati Veterans Affairs Medical Center between 2000 and 2005. Prescribed treatments were compared with the GOLD guidelines and each patient was classified as receiving less medications than recommended in the guidelines (<G), medications according to the guidelines (=G), or more medications than recommended (>G).
Respiratory medications were <G for 54%, =G in 33%, and >G for 14% of the patients studied. For GOLD stages 1 and 2,
Respiratory medications prescribed for an unselected population with a broad range of COPD severity complied poorly with the GOLD pharmacologic treatment guidelines but correlated with the number of prior respiratory health care visits.
在未选择的 COPD 患者人群中,先前的医疗保健利用与呼吸药物处方之间的关系尚不清楚。
我们确定了 2000 年至 2005 年间辛辛那提退伍军人事务医疗中心的 523 名 COPD 退伍军人的处方呼吸药物和呼吸及非呼吸保健就诊情况。将所开处方的治疗药物与 GOLD 指南进行了比较,并且将每位患者分为以下三种情况:推荐药物用量以下(<G)、推荐药物用量(=G)或推荐药物用量以上(>G)。
研究中,<G、=G 和 >G 患者分别占 54%、33%和 14%。对于 GOLD 1 期和 2 期,<G 患者在 12 个月内的呼吸就诊次数最少,而 >G 患者的呼吸就诊次数最多(0.31 +/- 0.073(0.21, 0.47)、0.75 +/- 0.5(0.37, 1.5)、1.1 +/- 0.27(0.74, 1.6)次/人/年,<G、=G、>G,分别为平均值+标准误差(SEM)(95%置信区间),2 自由度(df)ANOVA P < 0.001 用于处方效应)。对于 GOLD 3 期和 4 期,与 =G 相比,<G 与显著较少的先前呼吸就诊相关(0.78 +/- 0.11(0.6, 1.0)和 2.4 +/- 0.47(1.9, 3.1)次/人/年,P < 0.001)。GOLD 1 期和 2 期的非呼吸保健就诊次数,按处方水平无差异(3.1 +/- 0.24(2.6, 3.5)、3.1 +/- 0.46(2.1, 4.6)和 4.1 +/- 0.55(3.3, 5.1)次/人/年,<G、=G、>G,2 df ANOVA P = 0.096),或 GOLD 3 期和 4 期(3.6 +/- 0.25(3.2, 4.1)和 4.0 +/- 0.44(3.3, 4.9)次/人/年,<G 和 =G,P = 0.36)。
为具有广泛 COPD 严重程度的未选择人群开具的呼吸药物处方与 GOLD 药理学治疗指南不符,但与先前的呼吸保健就诊次数相关。